Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
POLYSULPHATED GLYCOSAMINOGLYCAN
Novartis Animal Health UK Ltd
QM01AX12
250 Mg/Ml
Solution for Injection
N.S.A.I.D
Equine - Food
2010-07-02
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Adequan 250 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance Polysulphated glycosaminoglycan (PSGAG) 250 mg For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear, pale yellow aqueous solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Horse. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For treatment of lameness in horses due to traumatic or degenerative aseptic joint disease. 4.3 CONTRAINDICATIONS Do not use in animals with infected or actively inflamed joints or with severe degradation of joint cartilage. Do not use in animals with known sensitivity to the active ingredient. Do not use in cases of advanced renal or hepatic disease. Do not use in pregnant animals. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/06/2011_ _CRN 7010244_ _page number: 1_ 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS In the presence of an active joint inflammation, therapy with a suitable anti-inflammatory agent should be given prior to intra-articular treatment with Adequan. The anti-inflammatory treatment should be discontinued as soon as possible since steroidal and non-steroidal agents may contribute to the degeneration of cartilage. SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE VETERINARY MEDICINAL PRODUCT TO ANIMALS Care should be taken to avoid accidental self-injection. In the case of accidental eye or skin contact, wash the affected area thoroughly with copious amounts of water. If irritation persists, seek medical attention. 4.6 Lees het volledige document